ALZN Alzamend Neuro Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALZN

Price (delayed)

$1.13

Market cap

$4.3M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.18

Enterprise value

$1.59M

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 3
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 0
Highlights
ALZN's EPS has soared by 85% year-on-year and by 22% since the previous quarter
The quick ratio has shrunk by 76% QoQ and by 68% YoY
ALZN's net income has dropped by 67% year-on-year and by 20% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://alzamend.com/
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of ALZN

ALZN stock price

How has the Alzamend Neuro stock price performed over time
Intraday
-1.74%
1 week
-1.74%
1 month
1.8%
1 year
-71.54%
YTD
-37.91%
QTD
6.6%

Financial performance

How have Alzamend Neuro's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$7.03M
Net income
-$7.04M
Gross margin
N/A
Net margin
N/A
ALZN's net income has dropped by 67% year-on-year and by 20% since the previous quarter
ALZN's operating income has dropped by 67% year-on-year and by 20% since the previous quarter

Price vs fundamentals

How does ALZN's price correlate with its fundamentals

Growth

What is Alzamend Neuro's growth rate over time

Valuation

What is Alzamend Neuro stock price valuation
P/E
N/A
P/B
1.97
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ALZN's EPS has soared by 85% year-on-year and by 22% since the previous quarter
ALZN's equity has dropped by 50% since the previous quarter and by 37% year-on-year

Efficiency

How efficient is Alzamend Neuro business performance
Alzamend Neuro's ROE has soared by 62% YoY but it has decreased by 27% from the previous quarter
ALZN's ROA is down by 18% from the previous quarter

Dividends

What is ALZN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALZN.

Financial health

How did Alzamend Neuro financials performed over time
Alzamend Neuro's total assets is 118% more than its total liabilities
The company's total liabilities has surged by 159% QoQ and by 156% YoY
The quick ratio has shrunk by 76% QoQ and by 68% YoY
ALZN's debt is 100% smaller than its equity
ALZN's equity has dropped by 50% since the previous quarter and by 37% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.